ArticleCancer medicine2013
Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients.
Article in Cancer medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Bone Marrow Metastasis of Embryonal Rhabdomyosarcoma in an Adult, Confounding as Acute Leukemia: A Diagnostic Challenge.International journal of hematology-oncology and stem cell research · 2026Article
- Pleomorphic rhabdomyosarcoma in adults: a case report.Journal of medical case reports · 2025Article
- Embryonal rhabdomyosarcoma at an unusual age and in an atypical site: a case report.Journal of medical case reports · 2025Article
- Clinicopathological and treatment response characteristics of updated rhabdomyosarcoma histomolecular subtypes: An Asian population-based study.Asia-Pacific journal of clinical oncology · 2025Article
- Characterization of a pleomorphic rhabdomyosarcoma cell line.Scientific reports · 2025Article
- Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.Pediatric blood & cancer · 2024Article
- Adult head and neck rhabdomyosarcoma: radiotherapy- based treatment, outcomes, and predictors of survival.BMC cancer · 2024Article
- Evaluation of clinical and imaging features for differentiating rhabdomyosarcoma from neuroblastoma in pediatric soft tissue.Frontiers in oncology · 2024Article
- Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.BMC cancer · 2023Article
- Complete loss ofHGG advances · 2023Article
- Treatment of spinal rhabdomyosarcoma in adults: A case report and literature review of current evidence.Oncology letters · 2023Article
- Shedding a Light on the Challenges of Adolescents and Young Adults with Rhabdomyosarcoma.Cancers · 2022Review
- Baseline Characteristics, Prognostic Factors, and Treatment Outcomes for Adult Patients With Rhabdomyosarcoma (RMS).Cureus · 2022Article
- Particle beam radiation therapy for head and neck rhabdomyosarcoma in adults.Annals of translational medicine · 2022Article
- Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016.Cancer reports (Hoboken, N.J.) · 2022Article
- Gross perianal embryonal rhabdomyosarcoma with severe multiple bone metastases throughout the body: a case report.The Journal of international medical research · 2022Article
- Clinical and pathological characteristics, treatment outcome and prognostic factors in adult rhabdomyosarcoma: a monocentric retrospective study.The Pan African medical journal · 2022Article
- Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark.Sarcoma · 2021Article
- Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series.Medical oncology (Northwood, London, England) · 2019Article
- Small bowel metastasis from pulmonary rhabdomyosarcoma causing intussusception: a case report.BMC gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Adult rhabdomyosarcoma (RMS) is a rare tumor that has inferior outcome compared to younger patient population. The present work aims to study the age-related differences in management of adolescents and adults with RMS. Under an institutional review board-approved protocol, we retrospectively analyzed 239 patients, 10 years of age and greater, diagnosed with RMS at MD Anderson Cancer Center from 1957 through 2003. Of the 239 patients, 163 patients were nonmetastatic with a median overall survival (OS) of 3.8 years (95% CI 2.8-7.6). In the multivariate analysis, age >50 was significantly associated with shorter OS and recurrence-free survival (RFS) for primary patients. Metastases were present in 76 patients, the median OS was 1.4 years. Approximately 13% of metastatic patients <50 years old had a long-term survival exceeding 15 years. Multimodality therapy, including surgery, radiotherapy, and chemotherapy was significantly associated with longer OS in primary and metastatic patients. Use of bi- and triple modality treatment decreased in metastatic patients over 50 years of age compared to younger patients. RMS in adolescents and adults has a poor outcome compared with younger individuals. Increased use of multidisciplinary therapy may improve older patient clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.